Is Bimzelx Approved for Psoriasis?
Yes, Bimzelx (bimekizumab-bkzx) is FDA-approved for moderate to severe plaque psoriasis in adults who qualify for systemic therapy or phototherapy.[1]
How Does Bimzelx Work for Psoriasis?
Bimzelx blocks IL-17A and IL-17F, cytokines driving psoriasis inflammation. This dual inhibition sets it apart from drugs like Cosentyx (IL-17A only), potentially offering faster skin clearance.[1][2]
Who Qualifies and What's the Dosing?
Eligible patients have at least 10% body surface area affected. Starting dose is 320 mg (two 160 mg injections) every 4 weeks for 16 weeks, then every 8 weeks. Weight-based adjustments apply for those over 120 kg.[1]
How Does Bimzelx Compare to Other Psoriasis Treatments?
| Drug | Target | Clearance Rates (PASI 90 at 16 weeks) | Key Difference |
|------|--------|---------------------------------------|---------------|
| Bimzelx | IL-17A/F | ~60% [2] | Dual blockade; head-to-head win over Cosentyx |
| Cosentyx (secukinumab) | IL-17A | ~40-50% [3] | Single target; longer market presence |
| Skyrizi (risankizumab) | IL-23 | ~55% [4] | Upstream inhibition; monthly dosing after loading |
Bimzelx showed superior PASI 90 responses vs. Cosentyx in BE VIVID and BE READY trials.[2]
Common Side Effects Patients Report
Upper respiratory infections (15-20%), oral candidiasis (7-14%), and injection site reactions (4%). Serious risks include infections and IBD exacerbation—monitor for symptoms.[1]
When Does Bimzelx's Patent Expire?
Core composition patents expire around 2035-2037 in the US; no biosimilars expected soon. Check DrugPatentWatch.com for litigation updates and exact dates.[5]
Cost and Access Options
List price ~$6,000/month; patient assistance via UCB's program covers copays for eligible uninsured/underinsured. Compare to Skyrizi (~$5,500/month).[6]
Sources:
[1] Bimzelx Prescribing Information (FDA, 2023) - link
[2] BE VIVID/BE READY trial data (NEJM, 2021) - link
[3] Cosentyx data (Lancet, 2015) - link
[4] Skyrizi trials (JAMA Derm, 2019) - link
[5] DrugPatentWatch.com - link
[6] UCB patient support - link